Cord Blood Registry® Announces Thought Leadership Role at Cord Blood Connect
- None.
- None.
Marquee industry conference will showcase data from CBR's Newborn Possibilities Program®
"Cord Blood Connect is a critical meeting for public and family cord blood banks, allowing them a forum to discuss industry innovations, patient needs, and evolving industry standards," stated Holly Sheffield, President, CooperSurgical. "We are proud to be the Platinum Sponsor of this event, and to be presenting new scientific data, as well as moderating a forum with key industry voices to discuss the future of cord blood banking. Our presence and participation is one example of CooperSurgical's commitment to elevating this industry."
CBR's abstract titled "Experience with enrollments and releases within a medical needs program at a large
"We're delighted to see our Newborn Possibilities Program being highlighted as a poster presentation at Cord Blood Connect," commented Peter Bawin, Global Vice President, Commercial Life Sciences, CooperSurgical. "This program was designed with families in mind, especially if a specific health history indicated a medical need that may potentially be treated using newborn stem cells. As the largest private newborn stem cell company in the world, we are happy to take the lead in finding ways to expand access to more families, especially as the science continues to evolve around this area of medicine."
Mr. Bawin will be moderating a panel titled "Future of Cord Blood Banking" on Saturday, September 9th featuring global leaders from the major family and public cord blood banks. The panel will discuss challenges facing the industry, along with the opportunities that exist given the changing landscape in hematopoietic transplant and the growing field of cell therapies. It also plans to explore how cord blood banks can be proactive in shaping the future of the industry.
For more information about Cord Blood Connect and CBR's participation, please visit https://www.cb-association.org/cord-blood-connect.
About CBR by CooperSurgical
Cord Blood Registry® (CBR®) is the largest private newborn stem cell company in the world, helping parents store stem cells from cord blood and cord tissue for their children. Founded in 1994, CBR is the #1 choice for parents1 and most recommended by OB/GYNs for newborn stem cell preservation.2 The company has released over 700 samples intended for use in transplant medicine and regulated investigational regenerative medicine applications. CBR is here to help expand the possibilities of what newborn stem cell therapies can do for families and give parents the confidence to Bank on CBR™. More information can be found at www.cordblood.com.
About CooperSurgical
CooperSurgical® is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most in life. CooperSurgical is at the forefront of delivering innovative assisted reproductive technology and genomic solutions that enhance the work of ART professionals to the benefit of families. We currently offer over 600 clinically relevant medical devices to women's healthcare providers, including testing and treatment options.
CooperSurgical is a wholly-owned subsidiary of CooperCompanies (NYSE: COO). CooperSurgical, headquartered in Trumbull, CT, produces and markets a wide array of products and services for use by women's health care clinicians. More information can be found at www.coopersurgical.com.
About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in
Disclaimer:
The use of cord blood is determined by the treating physician and is influenced by many factors, including the patient's medical condition, the characteristics of the sample, and whether the cord blood should come from the patient or an appropriately matched donor. Cord blood has established uses in transplant medicine; however, its use in regenerative medicine is still being researched. There is no guarantee that potential medical applications being studied in the laboratory or clinical trials will become available.
Cord tissue use is still in early research stages, and there is no guarantee that treatments using cord tissue will be available in the future. Cord tissue is stored whole. Additional processing prior to use will be required to extract and prepare any of the multiple cell types from cryopreserved cord tissue. Cbr Systems, Inc.'s activities for
References:
- Internal source. Data on file.
- Blind survey, Egg Strategy, 10/19, funded by CBR.
Contact:
CooperSurgical
EvolveMKD
csi@evolvemkd.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cord-blood-registry-announces-thought-leadership-role-at-cord-blood-connect-301922405.html
SOURCE CooperSurgical®